 NEW YORK and LONDON, June 21, 2021 GLOBE NEWSWIRE -- Tiziana Life Sciences plc NASDAQ: TLSA, LSE: TILS, a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, is pleased to announce the appointment of Dr. Kevin Schutz, PharmD, as Vice-President of Regulatory Affairs. Dr. Schutz will lead regulatory interactions related to clinical studies in the United States, Europe and Asian countries. 